To: Huggenberg who wrote (1046 ) 5/29/2025 12:43:16 PM From: End2War 3 RecommendationsRecommended By
Read Replies (1) | Respond to A Chat GPT evaluation of the October 2024 article:Title: Recurrent Pancreatic Cancer Treated with N-803 and PD-L1 t-haNK Followed by an EGFR-targeted Nanocell Drug Conjugate Published in: The Oncologist , March 2024Link to article Summary of the Case Study This is a detailed compassionate-use report of a patient with recurrent metastatic pancreatic cancer (mPC) who had already failed three prior lines of therapy .First spIND protocol: Therapies used : N-803 (IL-15 superagonist to activate NK and CD8+ T cells) PD-L1 t-haNK cells (engineered NK cells with high-affinity CD16 targeting PD-L1 for enhanced ADCC) Aldoxorubicin (albumin-doxorubicin conjugate to improve tumor-targeted chemotherapy) Treatment duration : ~27 months Clinical result : Stable disease was achieved. A transient complete response was observed by ~14 months into therapy. Second spIND protocol (post-progression): Therapies used : E-EDV-D682 + EDV-GC , components of the EGFR-targeted nanocell delivery system Duration : Over 24 months Outcome : Maintained stable disease , with the patient still alive at the time of publication. Evaluation Scientific and Clinical Significance Exceptional Duration of Disease Control : Total of more than 4 years (27 months first-line + >24 months second-line) of disease stability in advanced pancreatic cancer , which is notoriously resistant to treatment. Immunotherapy + Targeted Delivery Synergy : The case demonstrates how sequential or combinatory regimens using engineered NK cells , immune-stimulatory cytokines , and targeted chemotherapy nanocells may extend survival and control tumor progression in difficult-to-treat cancers. Evidence of Activity : A complete response, even if transient, is rare in metastatic pancreatic cancer after third-line failure and may suggest significant immunologic engagement by IBRX’s technologies. Limitations Single-patient case report : Results cannot be generalized. There’s no control group, and spontaneous stabilization cannot be ruled out (though unlikely). Need for Clinical Trials : Further validation in controlled, multi-patient trials is necessary to determine real-world applicability and reproducibility. Significance for IBRX (ImmunityBio) Investors This case supports the clinical relevance of IBRX’s core immunotherapy platform , especially: N-803 (Anktiva) , which is currently in multiple trials (e.g., bladder cancer, NSCLC, and other solid tumors). PD-L1 t-haNK cells , which offer a dual targeting approach (NK activation + checkpoint modulation). Targeted nanocell conjugates (e.g., EDV platforms), which may provide a next-generation drug delivery system especially when combined with immunotherapies. Investor Takeaways : Validation of Platform : Demonstrates long-term disease control even after multiple therapy failures, reinforcing IBRX’s platform potential. Durability : Highlights a major differentiator versus many checkpoint-only approaches. Catalyst for Partnerships : The combination of immunotherapy and targeted delivery could attract strategic partnerships or expanded trials. Support for Expansion : If replicated, could justify new indications beyond bladder cancer and increase the addressable market for IBRX technologies. Conclusion This compassionate use case, while limited to a single patient, presents powerful anecdotal evidence supporting IBRX’s immunotherapy and drug delivery platforms in an extremely resistant cancer. For long-term IBRX investors, it affirms the underlying scientific thesis and suggests significant upside if further trials corroborate these findings.
